TELA Bio CEO Koblish separation agreement: 12-month salary, equity acceleration

TELA Bio, Inc.

Separation Agreement executed Aug 7, 2026; CEO departure effective Aug 3, 2026.
Severance: 12 months base salary paid ratably over 12 months; COBRA premiums paid for 12 months.
All equity awards accelerate and fully vest; option exercise period extended to Dec 31, 2027.
Performance stock units remain eligible to vest on 2026 revenue/gross margin goals; vest at target on change in control.
Includes general release and waiver of claims against TELA Bio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.